Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease?

被引:23
作者
Fallone, CA
Guyattt, GH
Armstrong, D
Wiklund, I
Degl'Innocenti, A
Heels-Ansdell, D
Barkun, AN
Chiba, N
Van Zanten, SJOV
El-Dika, S
Austin, P
Tanser, L
Schünemann, HJ
机构
[1] McGill Univ, Ctr Hlth, Div Gastroenterol, Montreal, PQ, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
[3] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[4] AstraZeneca R&D, Clin Sci, Molndal, Sweden
[5] Dalhousie Univ, Dept Med, Halifax, NS, Canada
[6] Univ Buffalo, Dept Med, Buffalo, NY USA
[7] AstraZeneca R&D, Mississauga, ON, Canada
关键词
D O I
10.1111/j.1365-2036.2004.02257.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The accuracy of physicians' assessment of the severity of gastro-oesophageal reflux disease is unclear. Aim: To correlate physician and patient assessment of gastro-ocsophageal reflux disease severity and its response to treatment. Methods: Adult uninvestigated gastro-oesophageal reflux disease patients (n = 217) completed symptom and health-related quality of life questionnaires at baseline and after treatment with esomeprazole 40 mg p.o. daily. Pearson coefficients quantified correlations between physician assessments and patient responses. Results: At baseline, the strongest correlations were heartburn severity (0.31), overall symptom severity (0.44) and a domain of the quality of life in reflux and dyspepsia questionnaire (0.31) (P < 0.001). Correlations of change with treatment were greater than baseline correlations: heartburn (0.39), overall symptoms (0.50) and global rate of change - stomach problems (0.72, all P < 0.001). The mean difference between the physicians' assessment of change and the patients' global rating of change was 0.20 (95% confidence intervals: 0.10-0.29) with physicians overestimating benefit. Conclusions: Correlations were often significant, although weak to moderate and better with symptom severity than with health-related quality of life instruments as well as with change after therapy than at baseline. Increasing attention to health-related quality of life may help physicians better understand patients' experience. In clinical trials, treatment success should be assessed by the patient as well as the physician.
引用
收藏
页码:1161 / 1169
页数:9
相关论文
共 35 条
[1]  
ARMSTRONG D, 2003, AM J GASTROENTEROL S, V98, pS48
[2]  
Bennett K, 1996, QUALITY LIFE PHARMAC, P259
[3]   OBSERVER VARIATION IN ASSESSMENT OF QUALITY-OF-LIFE IN PATIENTS WITH ESOPHAGEAL CANCER [J].
BLAZEBY, JM ;
WILLIAMS, MH ;
ALDERSON, D ;
FARNDON, JR .
BRITISH JOURNAL OF SURGERY, 1995, 82 (09) :1200-1203
[4]  
Carlsson R, 1998, SCAND J GASTROENTERO, V33, P1023
[5]  
Carr AJ, 1998, BRIT J RHEUMATOL, V37, P1
[6]   Review article: initial therapy of reflux disease with esomeprazole [J].
Dent, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 :18-20
[8]   QUALITY-OF-LIFE IN PATIENTS WITH UPPER GASTROINTESTINAL SYMPTOMS - AN IMPROVED EVALUATION OF TREATMENT REGIMENS [J].
DIMENAS, E ;
GLISE, H ;
HALLERBACK, B ;
HERNQVIST, H ;
SVEDLUND, J ;
WIKLUND, I .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (08) :681-687
[9]   Assessment of quality of life in outpatients with advanced cancer: The accuracy of clinician estimations and the relevance of spiritual well-being - A Hoosier Oncology Group Study [J].
Fisch, MJ ;
Titzer, ML ;
Kristeller, JL ;
Shen, JZ ;
Loehrer, PJ ;
Jung, SH ;
Passik, SD ;
Einhorn, LH .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2754-2759
[10]   Quality of life of homebound patients with advanced cancer: Assessments by patients, family members, and oncologists [J].
Grassi, L ;
Indelli, M ;
Maltoni, M ;
Falcini, F ;
Fabbri, L ;
Indelli, R .
JOURNAL OF PSYCHOSOCIAL ONCOLOGY, 1996, 14 (03) :31-45